Gastrointestinal ultrasound examination auxiliary developer and preparation method thereof
The gastrointestinal ultrasound examination auxiliary developer addresses uneven distribution and gas artifacts by using silica particles with biocompatible polymers and a temperature-sensitive thickener, ensuring stable and prolonged imaging quality.
Patent Information
- Application Number
- JP2023576101
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-10-12
- Filing Date
- 2023-04-12
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2043-04-12
AI Technical Summary
Existing gastrointestinal ultrasound contrast agents face issues with uneven distribution, sedimentation, and insufficient window time due to mismatched solid contrast particle sizes and viscosities, leading to suboptimal imaging and gas artifacts.
A gastrointestinal ultrasound examination auxiliary developer with a specific formulation of silica particles modified with biocompatible polymers, combined with a temperature-sensitive thickener, ensuring uniform density and viscosity changes to enhance imaging clarity and extend examination time.
The developer achieves stable, uniform distribution and prolonged window time by optimizing particle sizes and viscosities, reducing gas artifacts and improving ultrasound imaging quality.
Smart Images

Figure 0007595193000004 
Figure 0007595193000005 
Figure 0007595193000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a gastrointestinal ultrasound examination auxiliary developer and its preparation method, which belongs to the technical field of medical ultrasound examination. [Background technology]
[0002] The gastrointestinal tract occupies 3 / 4 of the abdominal cavity volume, constitutes the majority of the digestive tract, and is the most morbid organ in the digestive system, and is one of the most clinically morbid organs. To clarify the location and nature of lesions, various examination methods are often used as diagnostic aids. Examination methods of the gastrointestinal tract include upper gastrointestinal barium diet, gastroscopy, gastric CT, and MRI. Upper gastrointestinal barium diet is simple, painless, and easy for patients to accept, but barium diet is a radioactive substance, and the results depend on the coating and filling effect of barium and the experience of the examiner. Barium sulfate is relatively safe, but there are a small number of patients who experience side effects and complications such as allergy, barium poisoning, barium leakage, barium sulfate fecal stone embedment, and worsening constipation, and some cases may even lead to death. Therefore, clinical application is limited, especially in elderly patients, patients with constipation, pregnant women, barium allergy, and patients with acute upper gastrointestinal bleeding, and barium diet X-ray is not used as a routine diagnostic aid. Gastroscopy can depict the shape and color of the gastric mucosa, the location, size, and depth of the lesion, and can perform pathological examinations to observe the lesions under direct vision and clarify the nature of the lesions. However, gastroscopy can only show the structure of the lumen well, and cannot observe the layers of the stomach wall or the peristaltic movement of the stomach. Since gastroscopy is an interventional examination, most people, such as elderly patients with severe cardiopulmonary disease, patients in the acute stage of upper gastrointestinal perforation, patients with acute severe pharyngeal disease, patients in the acute stage of corrosive esophageal damage, and patients who cannot cooperate due to mental disorders, experience discomfort that cannot be tolerated by gastroscopy, which subjectively and objectively limits the application of gastroscopy. CT / MRI, which has high spatial resolution and clear anatomical structures, is an imaging diagnostic method often used for staging gastric cancer, but CT / MRI is not easily used to detect microlesions in the gastrointestinal tract and has low diagnostic value for other diseases of the gastrointestinal tract, so it is not used as a routine examination method.
[0003] Since the discovery of the piezoelectric effect and the converse piezoelectric effect in physics in the early 20th century, ultrasound has rapidly opened a chapter in the history of technology and become a common and important examination method in the solid organs of the digestive system due to its non-invasive, painless, inexpensive, well tolerated and non-radioactive nature.
[0004] At present, there are three types of gastrointestinal ultrasound examinations used in clinical practice: transabdominal gastrointestinal ultrasound examination, gastrointestinal filling ultrasound examination, and endoscopic ultrasound examination. Transabdominal gastrointestinal ultrasound examination is merely an examination for preliminary screening, while endoscopic ultrasound examination combines the advantages of endoscopy and ultrasound examination to compensate for their respective shortcomings, further improving the diagnostic level of endoscopy and ultrasound examination. However, due to its high cost, complicated operation, and certain trauma, it is limited to some large hospitals and is far from being popularized. Gastrointestinal filling ultrasound examination is a method of filling the gastrointestinal tract with contrast agent (also called auxiliary developer) to eliminate the interference of ultrasound caused by gas and contents in the gastrointestinal tract, improve the internal environment of gastrointestinal ultrasound examination, and more clearly depict the structure and lesions of the gastrointestinal wall. This is the development trend of ultrasound examination for gastrointestinal diseases and can be popularized. Contrast agents are mainly non-echoic aqueous type and echoic powder type, and the current application is mainly echoic powder type.
[0005] At present, the contrast agents on the Chinese market are mainly made by crushing, mixing and compounding locally available herbal medicines and raw materials. For example, the herbal preparations prepared by the herbal prescriptions listed in CN102441180B, CN103611173B, etc. have certain health management and treatment effects. The developing assistant listed in CN1721000A is made by crushing, mixing and blending the ingredients, and has a better ultrasound image display effect, but before use, it needs to be directly brewed with 90-100 ° C hot water, stirred rapidly to form a uniform paste solution, and then cooled to a suitable temperature (generally controlled at 30-50 ° C), and then given to the patient to drink or instructed to take it to perform ultrasound examination at the same time.
[0006] In addition to Chinese herbal medicines and foodstuffs auxiliary developers, more convenient and effective auxiliary developer technologies have been developed. For example, the auxiliary developer described in patent CN107115534A uses a combination of osmotic contrast agents, swelling substances, stabilizers and defoamers to obtain an auxiliary developer with good compatibility and good filling effect. Meanwhile, patent CN109745570A, in addition to the use of osmotic contrast agents, increases the solid contrast agent, improves the development effect, and introduces bioactive substances such as bioactive glass, oligofructose and hyaluronic acid to play a certain health management role.
[0007] However, no matter what kind of auxiliary developer, there are certain limitations. For example, traditional Chinese medicine auxiliary developer has good health care effect, but the display interface under ultrasound is a low echo interface, the effect of auxiliary development is limited, the operation is complicated, and the waiting time is long; auxiliary developer with added solid contrast must first have appropriate size of solid contrast particles, if the solid contrast particles are too small or too large, the development effect is not good; if the solid contrast particles are too small, the brightness of the development interface is too low; if the solid contrast particles are too large, the graininess of the development interface is too strong; and the solid contrast density must be consistent with the liquid system of the auxiliary developer; if the density is inconsistent, it will affect the uniformity of the product, and the density If the density is too high, the solid contrast in the liquid auxiliary developer is easy to sink; if the density is too low, the solid contrast in the liquid auxiliary developer is easy to float; finally, it is necessary to add a swelling material to the auxiliary developer to increase the window time; when the viscosity of the auxiliary developer system is high, it is difficult to discharge gas in the gastrointestinal tract, which is easy to cause artifacts and affect the development effect; if the density of the solid contrast is too high or too low, it is difficult to shake evenly when sinking or floating occurs; if the viscosity of the auxiliary developer system is low, the window time is too short, and the gastrointestinal tract is easy to discharge the auxiliary developer quickly, which interferes with the clinician's gastrointestinal ultrasound diagnosis work. Summary of the Invention
[0008] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a gastrointestinal ultrasound examination auxiliary developer which has a stronger development auxiliary effect, is stable and uniform in product, is easy to expel excess gas in the gastrointestinal tract during use, and can increase the window time.
[0009] To achieve the above objectives, the present invention provides the following technical solutions: The gastrointestinal ultrasound examination auxiliary developer comprises, by weight, 2-4 parts of a thickener, 2-4 parts of an osmotic pressure regulator, 1.5-2.5 parts of a solid contrast, 0.02-0.04 parts of an antifoaming agent, 0.03-0.05 parts of a flavor corrector, 0.03-0.05 parts of a preservative, and 89.36-94.42 parts of purified water, and the density of the solid contrast is the same as that of the auxiliary developer liquid, and the density is 1.028g / ml to 1.089g / ml.
[0010] Further, the viscosity increasing agent is one or more of poloxamer 407, poloxamer 338, poloxamer 237 and poloxamer 188.
[0011] Furthermore, the osmotic pressure adjusting agent is at least one of xylitol and mannitol.
[0012] Furthermore, the solid contrast agent is a silica particle modified with a biocompatible polymer, and the biocompatible polymer is one or more of polyethylene glycol, branched polyethylene glycol, chitosan, alginic acid, hyaluronic acid, and polysiloxane.
[0013] Furthermore, the method of modifying the silica particles with the biocompatible polymer is one or more of the following: a sol-gel method, a one-step post-grafting method, a two-step post-grafting method, and a selective post-grafting method.
[0014] Furthermore, the silica particles are formed by mixing silica particles having different particle sizes in a specific ratio, and the specific recipe is as follows: silica particles having particle sizes of 75 to 85 mesh (excluding 85 mesh), 85 to 95 mesh (excluding 95 mesh), 95 to 105 mesh (excluding 105 mesh), and 105 to 120 mesh (excluding 120 mesh) are uniformly mixed in a mass ratio of (60-65):(15-20):(5-10):(5-20).
[0015] Further, the defoaming agent is at least one of an organosilicon-based defoaming agent and a polyether-based defoaming agent, the organosilicon-based defoaming agent may be dimethylsiloxane or the like, and the polyether-based defoaming agent may be polyoxypropylene oxide ethylene glyceryl ether or the like.
[0016] Further, the flavor corrector is one or more of strawberry flavor, lemon flavor, and apple flavor.
[0017] Additionally, the preservative is sodium deoxyacetate.
[0018] Furthermore, the gelation temperature of the auxiliary developer is 20 to 30° C. If the temperature is lower than the gelation temperature, the viscosity of the auxiliary developer is low, and if the temperature is higher than the gelation temperature, the viscosity of the auxiliary developer is high.
[0019] Furthermore, the auxiliary developer has a viscosity of 100 mPa·s or less at 20°C±0.2°C and a viscosity of 500 mPa·s or more at 37°C±0.2°C.
[0020] The present invention uses silica particles with different particle sizes in a specific proportion to optimize the development effect, and shows good development auxiliary effect in the ultrasonic image interface of the auxiliary developer; the silica particles are modified with biocompatible polymers, whose density is the same as that of the auxiliary developer liquid, and is not prone to sedimentation during storage, ensuring the stability of the product; by selecting a temperature-sensitive thickener, the viscosity is low at room temperature and high at 37°C; at the beginning when the auxiliary developer is delivered to the gastrointestinal tract, the overall temperature is low and the low viscosity state is conducive to the discharge of gastrointestinal gas, which can reduce the artifact problem caused by residual gas; after the auxiliary developer reaches the gastrointestinal tract for a certain period of time, the overall temperature is increased to body temperature, and the viscosity is increased, which extends the gastrointestinal examination window time, ensuring sufficient examination time.
[0021] Furthermore, the method for preparing the gastrointestinal ultrasound examination auxiliary developer includes the steps of collecting purified water, controlling its temperature to 2-4°C, slowly adding a thickener, an antifoaming agent, a flavor corrector, and a preservative in sequence at 800-1200 rpm, then adjusting the rotation speed to 50-100 rpm, slowly adding a solid contrast, then adjusting the rotation speed to 800-1200 rpm, adding an osmotic pressure regulator, stirring for 20-40 minutes, and finally dispensing the mixture into a 500 ml brown polyester bottle to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0022] The present invention has the following beneficial effects: 1. The auxiliary developer of the present invention has good auxiliary development effect. Through a large number of in vitro and in vivo experimental verifications, the development effect is optimized by using silica particles with different particle sizes in a specific proportion, and the auxiliary developer shows good auxiliary development effect at the ultrasonic image interface.
[0023] 2. The auxiliary developer of the present invention does not cause the floating or descent of solid contrast, so that the uniformity and stability of the product can be ensured. By modifying the silica particles with biocompatible polymer, their density is the same as that of the auxiliary developer liquid, so that there is no settling or floating during storage, and the stability of the product can be ensured.
[0024] 3. The auxiliary developer of the present invention can ensure sufficient window time while discharging excess gas in the gastrointestinal tract, and reduce the impact of gas artifacts on the gastrointestinal ultrasound diagnostic development auxiliary effect. The thickener sensitive to temperature is used, which has low viscosity at room temperature and high viscosity at 37℃. At the beginning when the auxiliary developer is delivered to the gastrointestinal tract, the overall temperature is low and the low viscosity state contributes to the discharge of gastrointestinal gas, reducing the artifact problem caused by residual gas. After the auxiliary developer reaches the gastrointestinal tract for a certain period of time, the overall temperature rises to body temperature, the viscosity increases, and the gastrointestinal examination window time is extended, ensuring sufficient examination time. [Brief description of the drawings]
[0025] [Figure 1] FIG. 2 is a graph showing the viscosity at 20° C.±0.2° C. of auxiliary developers for gastrointestinal ultrasound examination prepared in each of the examples and comparative examples of the present invention. [Diagram 2] FIG. 2 is a graph showing the viscosity at 37° C.±0.2° C. of auxiliary developers for gastrointestinal ultrasound examination prepared in each of the examples of the present invention and the comparative example. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0026] The present invention will be further described below with reference to examples. However, it should be noted that the following description is intended only to interpret the present invention and is not intended to limit the contents thereof.
[0027] Poloxamer 407, poloxamer 338, poloxamer 237 and poloxamer 188 used in the examples and comparative examples are all commercially available products.
[0028] Example 1 Take 91.84g of purified water, control its temperature at 2-4℃, and slowly add 2.7g poloxamer 338, 0.35g poloxamer 188, 0.03g dimethylsiloxane, 0.04g lemon flavoring, and 0.04g sodium deoxyacetate in sequence at 800-1200rpm, then adjust the rotation speed to 50-100rpm, slowly add 2g of polyethylene glycol-modified silica particles with a density of 1.06g / ml, and the silica particles will reach a temperature of 75-85℃. Mesh (except 85 mesh), 85 to 95 mesh (except 95 mesh), 95 to 105 mesh (except 105 mesh), and 105 to 120 mesh (except 120 mesh) are uniformly mixed in a mass ratio of 62.5:17.5:7.5:12.5, and then the rotation speed is adjusted to 800 to 1200 rpm, 3 g xylitol is added, and the mixture is stirred for 20 to 40 min. Finally, the mixture is dispensed into brown polyester bottles to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0029] Example 2 Take 89.41g of purified water, control its temperature at 2-4℃, and slowly add 3.7g of poloxamer 407, 0.25g of poloxamer 188, 0.04g of polyoxypropylene oxide ethylene glyceryl ether, 0.05g of strawberry flavoring, and 0.05g of sodium deoxyacetate in sequence at 800-1200rpm. Then, adjust the rotation speed to 50-100rpm and slowly add 2.5g of chitosan-modified silica particles with a density of 1.089g / ml. The silica particles are uniformly mixed in a mass ratio of 60:15:5:20 with 75 to 85 mesh (excluding 85 mesh), 85 to 95 mesh (excluding 95 mesh), 95 to 105 mesh (excluding 105 mesh), and 105 to 120 mesh (excluding 120 mesh), and then the rotation speed is adjusted to 800 to 1200 rpm, 4 g of mannitol is added, and the mixture is stirred for 20 to 40 minutes. Finally, the mixture is dispensed into brown polyester bottles to obtain an auxiliary developer for gastrointestinal ultrasound examination.
[0030] Example 3 Take 94.42g of purified water, control its temperature at 2-4℃, slowly add 2g poloxamer 407, 0.02g dimethylsiloxane, 0.03g apple fragrance, and 0.03g sodium deoxyacetate in sequence at 800-1200rpm, then adjust the rotation speed to 50-100rpm, slowly add 1.5g of silica particles modified with alginic acid, density 1.028g / ml, silica particles are 75-85 mesh (8 The mixture is then uniformly mixed in a mass ratio of 65:20:10:5 with 85 to 95 mesh (excluding 95 mesh), 95 to 105 mesh (excluding 105 mesh), and 105 to 120 mesh (excluding 120 mesh). The rotation speed is then adjusted to 800 to 1200 rpm, 2 g of xylitol is added, and the mixture is stirred for 20 to 40 min. Finally, the mixture is dispensed into brown polyester bottles to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0031] Example 4 Take 93.39g of purified water, control its temperature at 2-4℃, and slowly add 2.5g poloxamer 338, 0.5g poloxamer 237, 0.03g dimethylsiloxane, 0.04g lemon flavoring, and 0.04g sodium deoxyacetate in sequence at 800-1200rpm. Then, adjust the rotation speed to 50-100rpm, and slowly add 1.5g of silica particles modified with hyaluronic acid, with a density of 1.044g / ml. The silica particles are 75-85 mesh. The mixture is homogeneously mixed in a mass ratio of 62.5:17.5:7.5:12.5 with 85 mesh (excluding 85 mesh), 85 to 95 mesh (excluding 95 mesh), 95 to 105 mesh (excluding 105 mesh), and 105 to 120 mesh (excluding 120 mesh), and then the rotation speed is adjusted to 800 to 1200 rpm, 2 g of xylitol is added, and the mixture is stirred for 20 to 40 min. Finally, the mixture is dispensed into brown polyester bottles to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0032] Example 5 Take 90.39g of purified water, control its temperature at 2-4℃, and slowly add 2.9g poloxamer 407, 0.1g poloxamer 237, 0.03g dimethylsiloxane, 0.04g lemon flavoring, and 0.04g sodium deoxyacetate in sequence at 800-1200rpm. Then, adjust the rotation speed to 50-100rpm, and slowly add 2.5g of silica particles modified with polysiloxane, with a density of 1.078g / ml, and the silica particles are 75-85 methylsiloxane. The mesh (excluding 85 mesh), 85 to 95 mesh (excluding 95 mesh), 95 to 105 mesh (excluding 105 mesh), and 105 to 120 mesh (excluding 120 mesh) are uniformly mixed in a mass ratio of 62.5:17.5:7.5:12.5, and then the rotation speed is adjusted to 800 to 1200 rpm, 4 g of xylitol is added, and the mixture is stirred for 20 to 40 min. Finally, the mixture is dispensed into brown polyester bottles to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0033] Example 6 Take 91.85g of purified water, control its temperature at 2-4℃, and slowly add 2.7g poloxamer 407, 0.35g poloxamer 188, 0.02g dimethylsiloxane, 0.03g lemon flavoring, and 0.05g sodium deoxyacetate in sequence at 800-1200rpm, then adjust the rotation speed to 50-100rpm, slowly add 2g of silica particles modified with branched polyethylene glycol with a density of 1.061g / ml, and the silica particles will reach a temperature of 75-85℃. Mesh (except 85 mesh), 85 to 95 mesh (except 95 mesh), 95 to 105 mesh (except 105 mesh), and 105 to 120 mesh (except 120 mesh) are uniformly mixed in a mass ratio of 62.5:17.5:7.5:12.5, and then the rotation speed is adjusted to 800 to 1200 rpm, 3 g of xylitol is added, and the mixture is stirred for 20 to 40 min. Finally, the mixture is dispensed into brown polyester bottles to obtain the gastrointestinal ultrasound examination auxiliary developer.
[0034] Comparative Example 1 The steps were the same as in Example 1, except that the thickeners were 1.35 g sodium carboxymethylcellulose, 1.35 g hydroxypropylcellulose, and 0.35 g sodium hyaluronate.
[0035] Comparative Example 2 Each step was the same as in Example 1, except for the following: the thickeners were 0.7 g poloxamer 338 and 0.15 g poloxamer 188.
[0036] Comparative Example 3 Each step was the same as in Example 1, except for the following: the thickeners were 4.7 g poloxamer 338 and 0.65 g poloxamer 188.
[0037] Comparative Example 4 Each step is the same as in Example 1, except that the solid contrast silica particles are not modified with a biocompatible polymer.
[0038] Comparative Example 5 Each step was the same as in Example 1, except for the following points, and the particle size of the solid contrast silica particles was 75 to 85 mesh in all cases.
[0039] Comparative Example 6 Each step was the same as in Example 1, except for the following points, and the particle size of the solid contrast silica particles was 105 to 120 mesh in each case.
[0040] Silica particles modified with biocompatible polymers have been published in the following publications: "Research on the functionality of mesoporous silica nanomaterials and drug loading and in vitro release" (Wang Shuai. Research on the functionality of mesoporous silica nanomaterials and drug loading and in vitro release [D]. Guizhou University, 2020.), "Mesoporous silica nanoparticles dually modified with sulfhydryl and carboxyl groups and their preparation method" (CN107055553A), "Preparation of mesoporous silica nanoparticles modified with polyethylene glycol at the carboxyl end and their application" (CN108046276A), "Research on the support system based on mesoporous silica" (Shi Shaoming. Research on the support system based on mesoporous silica [D]. Changzhou University, 2021.), "Construction of aminated mesoporous silica / biopolymer-based drug release control system" (Li Shangji. Construction of drug release control system based on aminated mesoporous silica / biopolymer [D]. Changzhou University, 2021.), 《Pickering emulsion prepared from alginic acid derivative-activated silica nanoparticles》(Cheng Chunfeng, Li Jiacheng, Yan Huiqiong, Liu Ruolin, Wang Chunxiu, Lin Qiang. Pickering emulsion prepared from alginic acid derivative-activated silica nanoparticles [J]. Daily Chemical Industry, 2014, 44(05):241~246.), 《Preparation of functional mesoporous silica-loaded cisplatin nanodrug and its killing effect on breast cancer cells》(Liu Weikun, Zhang Meng, Li Binglong, Guan Xidong, Sun Mingshuang, He Yujing, Wang Chunxiao, Zhao Baochang, Zhang It was prepared by the method described in Jimei. Preparation of functional mesoporous silica-supported cisplatin nanodrug and its killing effect on breast cancer cells [J]. Journal of Taishan Medical College, 2019, 40(11): 801-805.) etc.
[0041] According to "YY / T 0681.1~2018 Part 1 of the Test Method for Packaging of Sterile Medical Devices: Guide for Accelerated Aging Test", the gastrointestinal ultrasound auxiliary developers prepared in Examples 1~6 and Comparative Examples 1~6 were subjected to accelerated aging at 60℃ for 65 days with a target shelf life of 2 years, and the uniformity of the samples after aging was recorded. The results are shown in Table 1 below.
[0042] [Table 1]
[0043] As can be seen from Table 1, in Examples 1 to 6, Comparative Example 1, Comparative Example 5 and Comparative Example 6, the samples after accelerated aging are uniform and there is no problem of solid particle floating or settling. The density of the silica particles modified with polyethylene glycol in Comparative Example 2 and the silica particles not modified with biocompatible polymer in Comparative Example 4 are both greater than the density of the corresponding sample liquid, so the phenomenon of solid particles sinking and the sample being non-uniform was observed. The density of the silica particles modified with polyethylene glycol in Comparative Example 3 is smaller than the density of the corresponding sample liquid, so the phenomenon of solid particles floating and the sample being non-uniform was observed. As shown in FIG. 1 and FIG. 2, the viscosities of the auxiliary developers for gastrointestinal ultrasound examination prepared in Examples 1 to 6 and Comparative Examples 1 to 6 at 20±0.2° C. and 37° C.±0.2° C. were measured.
[0044] As can be seen from FIG. 1 and FIG. 2, in Examples 1 to 6 and Comparative Examples 4 to 6, the viscosity at 20±0.2°C is less than 100 mPa·s and the viscosity at 37°C±0.2°C is more than 500 mPa·s. In Comparative Example 1, since the thickener is a non-temperature sensitive material, the difference in viscosity at 20±0.2°C and 37°C±0.2°C is not large, and both are 500 to 600 mPa·s. In Comparative Example 2, since the amount of thickener added is low, the viscosity at 37°C±0.2°C is 300 mPa·s or less. In Comparative Example 3, since the amount of thickener added is high, the viscosity at 20°C±0.2°C is 130 mPa·s or more.
[0045] The development effects of the gastrointestinal ultrasound examination auxiliary developers prepared in Examples 1 to 6 and Comparative Examples 1 to 6 were detected, and the specific method is as follows. Four 500ml samples were prepared for each group and stored at 20±0.2℃. Four beagle dogs, 9-11 months old, weighing approximately 10kg, were selected as the experimental animals. The 500ml samples were orally administered at 20±0.2℃ 15min before the imaging examination. The stomach and duodenal filling status were observed by ultrasound examination.
[0046] A score of 0 to 5 was used for the hierarchy and structure of the gastric and duodenal walls, the morphology of the stomach and duodenum, the expression of peristalsis and emptying function, window time satisfaction, and the effect of removing gas artifacts. The score standards are shown in Table 2 below, with higher scores indicating higher ability.
[0047] [Table 2]
[0048] The development effects of Examples 1 to 6 and Comparative Examples 1 to 6 are shown in detail in Table 3 below.
[0049] [Table 3]
[0050] As can be seen from Table 3, the average scores of Examples 1 to 6 are all above 4.9 points. As can be seen from the scores of each item, the sample development effects of Examples 1 to 6 are as follows: the gastrointestinal wall hierarchy and structure, the morphology of each part of the digestive tract, the digestive tract peristalsis and excretion function can be almost completely clearly distinguished, the gas artifacts can be completely removed, there is a sufficient stomach window time, and the observation requirements of normal speed can be met. The average scores of Comparative Example 1, Comparative Example 2, Comparative Example 3, and Comparative Example 4 are 2.35, 2.4, 2, and 2.95, respectively, which are significantly lower than the scores of Examples 1 to 6. As can be seen from the scores of each item, Comparative Example 1 uses a general thickener to ensure the window time of the sample, and its viscosity is similar to the final viscosity of the auxiliary developer that reaches the stomach in Examples 1 to 6, but there is no viscosity change at 20±0.2℃ to 37℃±0.2℃, and this viscosity makes it difficult for gastrointestinal gas to be discharged, and a large amount of gas artifact interference is displayed in the ultrasound image. In addition to the high score of the window time, the other scores are all low. In Comparative Example 2 and Comparative Example 3, the viscosity increased at 20±0.2℃~37±0.2℃, but the amount of thickener added was too low or too high, so the viscosity at 20±0.2℃ was also too low or too high, and the solid particle density was different from the density of the sample liquid, so even if the product was shaken uniformly, the ultrasound image was uneven after it reached the stomach, and the overall score was low. In Comparative Example 4, the solid contrast was not modified with a biocompatible polymer, so it was easy to settle in the stomach, and the gastrointestinal ultrasound interface showed a high echogenic interface unevenness, so each item score was low. The average scores of Comparative Examples 5 and 6 were 4.1 and 4.15, respectively, which were relatively high. However, as can be seen from the scores of each item, the solid contrast particles in Comparative Examples 5 and 6 were not a mixture of silica particles of different particle sizes in a fixed ratio, so the particles were scattered and reflected uniformly. The scores of the gastrointestinal wall hierarchy and structure in the development effect, the morphology of each part of the digestive tract, and the digestive tract peristalsis and excretion function were all lower than those of the Examples.
[0051] The above-described embodiments are only some of the embodiments of the present invention, but not all of the embodiments. The detailed description of the embodiments of the present invention does not limit the scope of the present invention, but is intended to represent only selected embodiments of the present invention. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative labor are all included in the protection scope of the present invention.
Claims
1. In parts by weight, the composition comprises 2-4 parts of a thickening agent, 2-4 parts of an osmotic pressure adjusting agent, 1.5-2.5 parts of a solid contrast, 0.02-0.04 parts of an antifoaming agent, 0.03-0.05 parts of a flavor corrector, 0.03-0.05 parts of a preservative, and 89.36-94.42 parts of purified water, the density of the solid contrast being the same as the density of the auxiliary developer liquid, the thickening agent being one or more of poloxamer 407, poloxamer 338, poloxamer 237, and poloxamer 188, the solid contrast being silica particles modified with a biocompatible polymer, and the biocompatible polymer being a polyetherimide. the silica particles are a mixture of silica particles having different particle sizes in a specific ratio, the specific recipe being as follows: silica particles having particle sizes of 75-85 mesh, 85-95 mesh, 95-105 mesh, and 105-120 mesh are uniformly mixed in a mass ratio of (60-65):(15-20):(5-10):(5-20), and the preservative is sodium deoxyacetate.
2. 2. The developer according to claim 1, wherein the osmotic pressure adjusting agent is at least one of xylitol and mannitol.
3. The gastrointestinal ultrasound examination auxiliary developer according to claim 1, characterized in that the method for modifying the silica particles with the biocompatible polymer is one or more of a sol-gel method, a one-stage post-grafting method, a two-stage post-grafting method, and a selective post-grafting method.
4. The gastrointestinal ultrasound examination auxiliary developer according to claim 1, characterized in that the antifoaming agent is at least one of an organosilicon-based antifoaming agent and a polyether-based antifoaming agent, and the flavor corrector is one or more of strawberry flavor, lemon flavor and apple flavor.
5. 5. The gastrointestinal ultrasound examination auxiliary developer according to claim 4, wherein the organosilicon-based antifoaming agent is dimethylsiloxane, and the polyether-based antifoaming agent is polyoxypropylene oxide ethylene glyceryl ether.
6. The auxiliary developer for gastrointestinal ultrasound examination according to any one of claims 1 to 5, characterized in that the gelation temperature of the auxiliary developer is 20 to 30°C, the viscosity of the auxiliary developer decreases when the temperature is lower than the gelation temperature, and the viscosity of the auxiliary developer increases when the temperature is higher than the gelation temperature, and the viscosity of the auxiliary developer at 20±0.2°C is 100 mPa·s or less and at 37°C±0.2°C is 500 mPa·s or more.
7. A method for preparing the gastrointestinal ultrasound examination auxiliary developer according to any one of claims 1 to 6, comprising the steps of: collecting purified water, controlling its temperature to 2-4°C, slowly adding a thickener, an antifoaming agent, a flavor corrector, and a preservative in that order at 800-1200 rpm, then adjusting the rotation speed to 50-100 rpm, slowly adding a solid contrast, then adjusting the rotation speed to 800-1200 rpm, adding an osmotic pressure regulator, stirring for 20-40 min, and finally dispensing the mixture into a 500 ml brown polyester bottle to obtain a gastrointestinal ultrasound examination auxiliary developer.
Citation Information
Patent Citations
Mercapto-carboxyl dual-modified mesoporous silica nanoparticles and preparation method therefor
CN107055553A
Preparation method and application of carboxyl terminated polyethylene glycol modified mesoporous silica nano particles
CN108046276A
Targeted Porous Inorganic Ultrasound Contrast Agent
JP2003504419A
